StockNews.AI
EDIT
StockNews.AI
113 days

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

1. Editas will present at ASGCT, emphasizing in vivo gene editing advancements. 2. One oral presentation focuses on targeted lipid nanoparticles for hematopoietic stem cells. 3. Preclinical data shows promise for liver-targeted CRISPR editing therapies. 4. The company plans to address diseases through a differentiated gene upregulation strategy. 5. Editas aims to advance its pipeline for serious diseases globally.

6m saved
Insight
Article

FAQ

Why Bullish?

Editas' strong presentation of preclinical results can enhance investor confidence, similar to past biotech successes following conference disclosures.

How important is it?

The article showcases crucial advancements that could positively influence EDIT's market position and future growth.

Why Long Term?

The ongoing development and potential future FDA approvals from progress at ASGCT can drive significant long-term value.

Related Companies

CRSPNTLASGMO
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and/or hematopoietic stem cells (HSCs) in bone marrow.Preclinical proof of concept for an undisclosed liver target using in vivo CRISPR editing to upregulate target protein expression and reduce a disease-associated biomarker in a relevant mouse disease model.Proof of concept results from the first in vivo mouse and NHP studies demonstrating high levels of target gene editing in the liver and corresponding biomarker response following intravenous administration of AsCas12a messenger RNA (mRNA) and chemically modified guide RNAs (gRNAs) delivered using LNPs from Genevant.Additional preclinical data demonstrating in vivo gene editing capabilities towards developing transformative in vivo medicines, including guide modification and targeting moiety optimizations to increase potency and improve gene editing outcomes in vivo. “Editas Medicine is making significant progress towards the clinic with our in vivo medicines in preclinical development for people living with serious diseases,” said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We look forward to sharing further proof of concept data at ASGCT, including preclinical data confirming our ability to increase the level of a protein to address diseases caused by loss of function or deleterious mutations via our differentiated gene upregulation editing strategy. Our progress with tLNP delivery highlights the potential to execute our gene upregulation strategy across multiple tissues with our ‘plug ‘n play’ approach.” The complete list of Editas Medicine presentations is below. Abstracts can be accessed on the ASGCT website, and the presentations will be posted on the Editas Medicine website during the conference. Oral Presentation:Title: In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid NanoparticlesSession Date and Time: Wednesday, May 14, 2025, 1:30 p.m. – 1:45 p.m. CT Session Title: Translational Applications of Base and Prime EditorsRoom: 265-268Final Abstract Number: AMA353 Poster Presentations:Title: Design and Development of Improved LNP Targeting Ligands for In Vivo Hematopoietic Stem Cell EditingSession Date and Time: Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CTSession Title: Tuesday Poster ReceptionPresentation Room: Poster Hall, Hall 12Final Abstract Number: AMA245 Title: Design of Chemically Modified AsCas12a Guide RNAs for Increased Potency of LNP-Delivered Gene Editing CargosSession Date and Time: Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CTSession Title: Tuesday Poster ReceptionPresentation Room: Poster Hall, Hall 12Final Abstract Number: AMA420 Title: In Vivo Gene Editing and Disease-Associated Biomarker Reduction for Multiple Liver Targets in Non-human Primate Using AsCas12a Nuclease Delivered by LNPSession Date and Time: Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CTSession Title: Wednesday Poster ReceptionPresentation Room: Poster Hall, Hall 12 Final Abstract Number: AMA640 Title: In Vivo CRISPR Editing of Genetic Regulatory Regions Results in Functional Upregulation of Target Protein and Meaningful Reduction of Disease-Associated Biomarker in MiceSession Date and Time: Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CTSession Title: Wednesday Poster ReceptionPresentation Room: Poster Hall, Hall 12 Final Abstract Number: AMA351 About Editas MedicineAs a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Related News